Esperion(ESPR) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update – Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million – – Q2 2025 U.S. Net Product Revenue Grew 42% Y/Y to $40.3 Million – – Total Retail Prescription Equivalents Increased 10% from First Quarter – – Reached Settlement Agreements with Three ANDA Filers Not to Market Generic Versions of NEXLETOL (bempedoic acid) Prior to 2040 – ® – First Quarter of Operating Income from Ongoing Business with Plans for Sustainable ...